Study design and patients
BYOND (ClinicalTrials.gov, NCT02228382) was an open-label, nonrandomized, single-arm phase 4 study of bosutinib for which the methods have been previously published [The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before study procedures began, and the protocol was approved by institutional review boards at each study site.